Dynavax (DVAX) Tops Q2 EPS by 64c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Dynavax Reports Second Quarter 2022 Financial Results
August 4, 2022 4:02 PM EDTQ2 2022 total revenue of $256.5 million, up 386% from $52.8 million for Q2 2021HEPLISAV-B® vaccine net product revenue of $32.7 million, up 139% from $13.7 million for Q2 2021CpG 1018® adjuvant net product revenue of $222.6 million, up 471% from $39.0 million for Q2 2021On track for second consecutive year of profitabilityConference call today at 4:30 p.m. ET/1:30 p.m. PT
EMERYVILLE, Calif., Aug. 4, 2022 /PRNewswire/ -- Dynavax Technologies... More
